Literature DB >> 2575574

Plasma somatostatin and vasoactive intestinal polypeptide responses to an oral mixed test meal in obese patients.

T Barreca1, R Franceschini, V Messina, A Cataldi, M Salvemini, E Rolandi.   

Abstract

Ten obese and 10 control subjects were studied in basal conditions and after ingestion of a standard mixed test meal. Blood glucose, insulin, somatostatin (SLI) and vasoactive intestinal polypeptide (VIP) concentrations were determined before and 30, 60, 90, 120, 180 and 240 min after the start of the meal. Basal SLI levels in the obese (14.4 +/- 0.7 ng/l) were not significantly different from those in the controls (15.5 +/- 0.8 ng/l), whereas after the meal a blunted secretory response was recorded. Baseline plasma VIP levels were higher in the obese (29.7 +/- 1.5 ng/l) than in the control subjects (19.8 +/- 1.3 ng/l) and, similarly to the controls, were unaffected by meal ingestion. Data suggest that in the course of obesity an enhanced VIP secretion in association with a diminished SLI responsiveness to meals occurs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2575574     DOI: 10.1159/000181123

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

1.  Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men.

Authors:  M Peracchi; F Carola; F Cavagnini; R Benti; B Bareggi; G Baccalaro; G Basilisco
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

2.  Vasoactive Intestinal Peptide Deficiency Is Associated With Altered Gut Microbiota Communities in Male and Female C57BL/6 Mice.

Authors:  Manpreet Bains; Caleb Laney; Annie E Wolfe; Megan Orr; James A Waschek; Aaron C Ericsson; Glenn P Dorsam
Journal:  Front Microbiol       Date:  2019-12-02       Impact factor: 5.640

3.  Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center.

Authors:  Olivia L Butler; Monica M Mekhael; Arslan Ahmed; Daniel J Cuthbertson; D Mark Pritchard
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-16       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.